Clinical application of dendrimer in cancer and COVID-19 therapy: a review
Abstract
Dendrimers are nanoparticles with unique characteristics. These characteristics allow these nanoparticles to be widely applied in medicine. It can be used as a therapy for various types of cancer. The dendrimers can also been use an alternative to accelerating the diagnosis and therapy of COVID-19. This review aimed to delve deeper into the myriad clinical applications of dendrimers in the treatment of various cancers and its potential use for the treatment or diagnosis of COVID-19. The databases used for this review were Google Scholar and Science Direct. The inclusion criteria for this review are articles published in 2018-2023. Articles other than the original articles and reviews we excluded from the study. Anticancer formulated in dendrimers have a better ability to eradicate cancer cells in the treatment of breast, colon, lung, prostate, skin, ovarian, and liver cancers compared to ordinary anticancer agents. Dendrimer in vivo, in vitro and phase II clinical trials can be used to deliver miRNA therapy or symptomatic drugs in COVID-19 patients and as vaccine delivery agents. The quality of molecular diagnosis of COVID-19 can also be improved with these nanoparticles. The use of dendrimers can improve the quality of management of cancer and COVID-19 patients.
References
Nikalje, AP. Nanotechnology and its applications in medicine. Med Chem 2015; 5(2):081-9.
https://doi.org/10.4172/2161-0444.1000247
Carvalho MR, Reis RL, Oliveira JM. Dendrimer nanoparticles for colorectal cancer applications. J Mater Chem B 2020; 8(6):1128-38.
https://doi.org/10.1039/c9tb02289a
Sasi S, Joseph SK, Arian AM, Thomas S, Amrutha VU, Arya GK, et al. An updated review on the application of dendrimers as successful nanocarriers for brain delivery of therapeutic moieties. Int J Appl Pharm 2021; 13(1):1-9.
https://doi.org/10.22159/ijap.2021v13i1.39812
Mittal P, Saharan A, Verma R, Altalbawy FMA, Alfaidi MA, Batiha GE, et al. Dendrimers: A New Race of Pharmaceutical Nanocarriers. Biomed Rest Int 2021; 2021:8844030.
https://doi.org/10.1155/2021/8844030
Abbasi E, Aval SF, Akbarzadeh A, Milani M, Nasrabadi HT, Joo SW, et al. Dendrimers: synthesis, applications, and properties. Nanoscale Res Lett 2014; 9(1):247.
https://doi.org/10.1186/1556-276X-9-247
Marques BL, Carvalho GA, Freitas EMM, Chiareli RA, Barbosa TG, Di Araújo AGP, et al. The role of neurogenesis in neurorepair after ischemic stroke. Semin Cell Dev Biol 2019; 95:98-110.
https://doi.org/10.1016/j.semcdb.2018.12.003
Sherje AP, Jadhav M, Dravyakar BR, Kadam D. Dendrimers: a versatile nanocarrier for drug delivery and targeting. Int J Pharm 2018; 548(1):707-20.
https://doi.org/10.1016/j.ijpharm.2018.07.030
Chis AA, Debora C, Morgovan C, Arseniu AM, Rus LL, Butuca A, et al. Applications and limitations of dendrimers in biomedicine. Moleculs 2020; 25(17):3982.
https://doi.org/10.3390/molecules25173982
Chhikara BS, Parang K. Global Cancer Statistics 2022: the trends projection analysis. Chemical Biology Letters 2023;10(1):451.
Jiang P, Liang B, Zhang Z, Fan B, Zeng L, Zhou Z, et al. New insights into nanosystems for non-small-cell lung cancer: diagnosis and treatment. RSC Adv 2023; 13(18):19540-64.
https://doi.org/10.1039/D3RA03099G
Bhavana V, Thakor P, Singh SB, Mehra NK. COVID-19: Pathophysiology, treatment options, nanotechnology approaches, and research agenda to combating the SARS-CoV2 pandemic. Life Sci 2020; 261:118336.
https://doi.org/10.1016/j.lfs.2020.118336
Saravanan M, Mostafavi E, Vincent S, Negash H, Andavar R, Perumal V, et al. Nanotechnology-based approaches for emerging and re-emerging viruses: special emphasis on COVID-19. Microb Pathog 2021; 156:104908.
https://doi.org/10.1016/j.micpath.2021.104908
Hasanzadeh A, Alamdaran M, Ahmadi S, Nourizadeh H, Bagherzadeh MA, Mofazzal Jahromi MA, et al. Nanotechnology against COVID-19: Immunization, diagnostic and therapeutic studies. J Control Release 2021; 336:354-74.
https://doi.org/10.1016/j.jconrel.2021.06.036
Kandeel M, Al-Taher A, Park BK, Kwon HJ, Al-Nazawi M. A pilot study of the antiviral activity of anionic and cationic polyamidoamine dendrimers against the Middle East respiratory syndrome coronavirus. J Med Virol 2020; 92(9):1665-70.
https://doi.org/10.1002/jmv.25928
Bober Z, Bartusik-Aebisher D, Aebisher D. Application of dendrimers in anticancer diagnostics and therapy. Molecules 2022; 27(10):3237.
https://doi.org/10.3390/molecules27103237
Montané X, Bajek A, Roszkowski K, Montornés JM, Giamberini M, Roszkowski S, et al. Encapsulation for cancer therapy. Molecules 2020; 25(7):1605.
https://doi.org/10.3390/molecules25071605
Navya PN, Kaphle A, Srinivas SP, Bhargava SK, Rotello VM, Daima HK. Current trends and challenges in cancer management and therapy using designer nanomaterials. Nano Converg 2019; 6(1):23.
https://doi.org/10.1186/s40580-019-0193-2
Raj S, Khurana S, Choudhari R, Kesari KK, Kamal MA, Garg N, et al. Specific targeting cancer cells with nanoparticles and drug delivery in cancer therapy. Semin Cancer Biol 2021; 69:166-77.
https://doi.org/10.1016/j.semcancer.2019.11.002
Sheikh A, Abourehab M, Tulbah A, Kesharwani P. Aptamer-grafted, cell membrane-coated dendrimer loaded with doxorubicin as a targeted nanosystem against epithelial cellular adhesion molecule (EpCAM) for triple negative breast cancer therapy. J Drug Deliv Sci Technol 2023; 86:104745.
https://doi.org/10.1016/j.jddst.2023.104745
Janaszewska A, Lazniewska J, Trzepiński P, Marcinkowska M, Klajnert-Maculewicz B. Cytotoxicity of dendrimers. Biomolecules 2019; 9(8):330.
https://doi.org/10.3390/biom9080330
Surekha B, Kommana NS, Dubey SK, Kumar AVP, Shukla R, Kesharwani P. PAMAM dendrimer as a talented multifunctional biomimetic nanocarrier for cancer diagnosis and therapy. Colloids Surf B Biointerfaces 2021; 204:111837.
https://doi.org/10.1016/j.colsurfb.2021.111837
Mishra MK, Kotta K, Hali M, Wykes S, Gerard HC, Hudson AP, et al. PAMAM dendrimer-azithromycin conjugate nanodevices for the treatment of Chlamydia trachomatis infections. Nanomedicine 2011; 7(6):935-44.
https://doi.org/10.1016/j.nano.2011.04.008
Jangid AK, Patel K, Joshi U, Patel S, Singh A, Kulhari DP, et al. PEGylated G4 dendrimers as a promising nanocarrier for piperlongumine delivery: synthesis, characterization, and anticancer activity. Eur Polymer J 2022; 179(31):111547.
https://doi.org/10.1016/j.eurpolymj.2022.111547
Aso E, Martinsson I, Appelhans D, Effenberg C, Benseny-Cases N, Cladera J, et al. Poly(propylene imine) dendrimers with histidine-maltose shell as novel type of nanoparticles for synapse and memory protection. Nanomedicine 2019; 17:198-209.
https://doi.org/10.1016/j.nano.2019.01.010
Chen S, Huang S, Li Y, Zhou C. Recent advances in epsilon-poly-L-lysine and L-lysine-based dendrimer synthesis, modification, and biomedical applications. Front Chem 2021; 9:659304.
https://doi.org/10.3389/fchem.2021.659304
Gorzkiewicz M, Kopeć O, Janaszewska A, Konopka M, Pędziwiatr-Werbicka E, Tarasenko II, et al. Poly(lysine) dendrimers form complexes with siRNA and provide its efficient uptake by myeloid cells: model studies for therapeutic nucleic acid delivery. Int J Mol Sci 2020; 21(9):3138.
https://doi.org/10.3390/ijms21093138.
Guo XL, Kang XX, Wang YQ, Zhang XJ, Li CJ, Liu Y, et al. Co-delivery of cisplatin and doxorubicin by covalently conjugating with polyamidoamine dendrimer for enhanced synergistic cancer therapy. Acta Biomater 2019; 84:367-77.
https://doi.org/10.1016/j.actbio.2018.12.007
Bartusik-Aebisher D, Chrzanowski G, Bober Z, Aebisher D. An analytical study of trastuzumab-dendrimer-fluorine drug delivery system in breast cancer therapy in vitro. Biomed Pharmacother 2021; 133:111053.
https://doi.org/10.1016/j.biopha.2020.111053
Lewińska A, Wróbel K, Błoniarz D, Adamczyk-Grochala J, Wołowiec S, Wnuk M. Lapatinib- and fulvestrant-PAMAM dendrimer conjugates promote apoptosis in chemotherapy-induced senescent breast cancer cells with different receptor status. Biomater Adv 2022; 140:213047.
https://doi.org/10.1016/j.bioadv.2022.213047
Kheraldine H, Gupta I, Alhussain H, Jabeen A, Cyprian FS, Akhtar S, et al. Substantial cell apoptosis provoked by naked PAMAM dendrimers in HER2-positive human breast cancer via JNK and ERK1/ERK2 signalling pathways. Comput Struct Biotechnol J 2021; 19:2881-90.
https://doi.org/10.1016/j.csbj.2021.05.011
Thuy LT, Kang N, Choi M, Lee M, Choi JS. Dendrimeric micelles composed of polyamidoamine dendrimer-peptide-cholesterol conjugates as drug carriers for the treatment of melanoma and bacterial infection. J Ind Eng Chem 2022; 114:361-376.
https://doi.org/10.1016/j.jiec.2022.07.026
Ma G, Du X, Zhu J, Xu F, Yu H, Li J. Multi-functionalized dendrimers for targeted co-delivery of sorafenib and paclitaxel in liver cancers. J Drug Deliv Sci Technol 2021; 63:102493.
https://doi.org/10.1016/j.jddst.2021.102493
Zhu F, Xu L, Li X, Li Z, Wang J, Chen H, et al. Co-delivery of gefitinib and hematoporphyrin by aptamer-modified fluorinated dendrimer for hypoxia alleviation and enhanced synergistic chemo-photodynamic therapy of NSCLC. Eur J Pharm Sci 2021; 167:106004.
https://doi.org/10.1016/j.ejps.2021.106004
Amreddy N, Babu A, Panneerselvam J, Srivastava A, Muralidharan R, Chen A, et al. Chemo-biologic combinatorial drug delivery using folate receptor-targeted dendrimer nanoparticles for lung cancer treatment. Nanomedicine 2018; 14(2):373-84.
https://doi.org/10.1016/j.nano.2017.11.010
Lee CS, Kim TW, Kang Y, Ju Y, Ryu J, Hong H, et al. Targeted drug delivery nanocarriers based on hyaluronic acid-decorated dendrimer encapsulating gold nanoparticles for ovarian cancer therapy. Mater Today Chem 2022; 26:101083.
https://doi.org/10.1016/j.mtchem.2022.101083
Dong Y, Chen Y, Zhu D, Shi K, Ma C, Zhang W, et al. Self-assembly of amphiphilic phospholipid peptide dendrimer-based nanovectors for effective delivery of siRNA therapeutics in prostate cancer therapy. J Control Release; 322:416-25.
https://doi.org/10.1016/j.jconrel.2020.04.003
Itani R, Tobaiqy M, Al Faraj A. Optimizing use of theranostic nanoparticles as a life-saving strategy for treating COVID-19 patients. Theranostics 2020; 10(13):5932-42.
https://doi.org/10.7150/thno.46691
Mignani S, Shi X, Karpus A, Lentini G, Majoral JP. Functionalized dendrimer platforms as a new forefront arsenal targeting SARS-CoV-2: an opportunity. Pharmaceutics 2021; 13(9):1513.
https://doi.org/10.3390/pharmaceutics13091513
Gusdon AM, Faraday N, Aita JS, Kumar S, Mehta I, Choi HA, et al. Dendrimer nanotherapy for severe COVID-19 attenuates inflammation and neurological injury markers and improves outcomes in a phase2a clinical trial. Sci Transl Med 2022; 14(654):eabo2652.
https://doi.org/10.1126/scitranslmed.abo2652
Panda M, Kalita E, Singh S, Kumar K, Rao A, Prajapati VK. MiRNA-SARS-CoV-2 dialogue and prospective anti-COVID-19 therapies. Life Sci 2022; 305:120761.
https://doi.org/10.1016/j.lfs.2022.120761
Abd Elkodous M, Olojede SO, Morsi M, El-Sayyad GS. Nanomaterial-based drug delivery systems as promising carriers for patients with COVID-19. RSC Adv 2021; 11(43):26463-80.
https://doi.org/10.1039/d1ra04835j
Khaitov M, Nikonova A, Kofiadi I, Shilovskiy I, Smirnov V, Elisytina O, et al. Treatment of COVID-19 patients with a SARS-CoV-2-specific siRNA-peptide dendrimer formulation. Allergy 2023; 78(6):1639-53.
https://doi.org/10.1111/all.15663
Asdaq SMB, Ikbal AMA, Sahu RK, Bhattacharjee B, Paul T, Deka B, et al. Nanotechnology integration for SARS-CoV-2 diagnosis and treatment: an approach to preventing pandemic. Nanomaterials (Basel) 2021; 11(7):1841.
https://doi.org/10.3390/nano11071841
Paull JRA, Heery GP, Bobardt MD, Castellarnau A, Luscombe CA, Fairley JK, et al. Virucidal and antiviral activity of astodrimer sodium against SARS-CoV-2 in vitro. Antiviral Res 2021; 191:105089.
https://doi.org/10.1016/j.antiviral.2021.105089
Zare M, Sillanpää M, Ramakrishna S. Essential role of quantum science and nanoscience in antiviral strategies for COVID-19. Mater Adv 2021; 7:2188-99.
https://doi.org/10.1039/D1MA00060H
Farzin L, Sadjadi S, Sheini A, Mohagheghpour E. A nanoscale genosensor for early detection of COVID-19 by voltammetric determination of RNA-dependent RNA polymerase (RdRP) sequence of SARS-CoV-2 virus. Mikrochim Acta 2021; 188(4):121.
https://doi.org/10.1007/s00604-021-04773-6.
Kesharwani P, Jain K, Jain NK. Dendrimer as nanocarrier for drug delivery. Prog Polym Sci 2014; 39(2):268-307.
https://doi.org/10.1016/j.progpolymsci.2013.07.005
Hsu HJ, Bugno J, Lee SR, Hong S. Dendrimer-based nanocarriers: a versatile platform for drug delivery. Wiley Interdiscip Rev Nanomed Nanobiotechnol 2017; 9(1):e1409.
